{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-326406","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.461729+00:00","generated_at":"2026-06-28T09:28:17.731469+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monte Rosa names first development candidate MRT-2359 targeting GSPT1; Q3 net loss $19.8M","bullets":["Selected MRT-2359 as first development candidate; initiated IND-enabling studies for mid-2022 IND submission.","Q3 2021 net loss $19.8M vs $6.6M in Q3 2020; R&D expenses $15.1M up from $5.5M.","Cash and equivalents $367M as of Sept 30, 2021, expected to fund operations into late 2024.","Presented preclinical data on GSPT1 degraders for Myc-driven cancers at AACR-NCI-EORTC.","NEK7 program in lead optimization; expect at least one more program to enter lead optimization in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-326406","json":"https://secwatch.observer/filing/0001193125-21-326406.json","markdown":"https://secwatch.observer/filing/0001193125-21-326406.md","text":"https://secwatch.observer/filing/0001193125-21-326406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312521326406/0001193125-21-326406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312521326406/d244737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:28:17.731469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}